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Left Ventricular Ejection Fraction And Severe Mitral Regurgitation After
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Background: Data is limited on the long-term outcome of patients with a left ven-
tricular ejection fraction (LV-EF) 25% and severe mitral regurgitation (MR) after
percutaneous edge-to-edge mitral valve repair.
Methods: From 2009 to 2012, 34 patients with a LV-EF 25% and severe MR were
intended to treat with percutaneous edge-to-edge mitral valve repair in the two uni-
versity hospitals of Munich.
Results: Long-term follow-up (up to 4.5 years) revealed a high 1-year mortality of
50% and the putative existence of two subgroups, one with a poor short-term and a
second one with a favourable long-term outcome. In an univariate Cox proportional
hazard model, NYHA functional class IV (hazard ratio [HR] 4.1, p¼0.009), cardio-
genic shock (HR 8.6, p¼0.015), lack of hypertension (HR 3.9, p¼0.013), low
tricuspid annular plane systolic excursion (TAPSE < 14mm)(HR 4.0, p¼0.035),
severely impaired RV-function (HR 3.3, p¼0.014), elevated right ventricular tricuspid
pressure gradient (RVTG  30mmHg)(p¼0.0016), dialysis (HR 6.6, p¼0.001),
EuroSCORE II (HR 1.3, p¼0.008) and STS risk score (HR 1.4, p¼0.004) were
signiﬁcantly associated with 1-year mortality. Dialysis was an independent predictor
of 1-year mortality.
Conclusions: Percutaneous edge-to-edge mitral valve repair possibly leads to a
favourable long-term outcome in a subgroup of patients with a LV-EF 25% and
severe MR. Predictors like NYHA functional class, cardiogenic shock, TAPSE, RV-
function, RVTG, the need for dialysis, EuroSCORE II and STS risk score might be
used to consider percutaneous edge-to-edge mitral valve repair primarily for patients
with favourable prognosis.TCT-800
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Background: We sought to evaluate the improvement in quality of life (QOL) in
patients with severe degenerative mitral regurgitation (DMR) at prohibitive surgical
risk undergoing transcatheter mitral valve repair with the MitraClip.
Methods: MitraClip repair was performed in 21 prohibitive risk DMR patients with
4+ MR after a multi-disciplinary heart team deemed them to be ineligible for surgery.
The Kansas City Cardiomyopathy Questionnaire (KCCQ) was administered at base-
line and one-month follow-up to assess QOL.
Results:Mean age was 789 years, and mean STS score was 12.2%. Twenty patients
(95.3%) had successful deployment of the MitraClip device. There were no proceduralB234 JACC Vol 64/11/Suppl B j September 13–17, 2014 j Tdeaths. At 30-day follow-up there were two deaths (9.5%), 1 due to respiratory failure
at 48 hours and 1 due to a stroke at 3 weeks. At 1-month follow-up, 17 patients
(81.0%) had grade 1-2+ MR. QOL as assessed by the KCCQ in 18 patients was
signiﬁcantly improved (P< 0.001) in 1-month survivors (Figure). Eight different
quality domains were used for assessment of QOL. These included activity (p¼0.002),
edema (p¼0.001), fatigue (0.001), shortness of breath (p¼0.001), orthopnea
(p¼0.003), enjoyment of life (p-0.001), satisfaction at status quo health (p¼0.001) and
activity limitation (p¼0.01). There was a signiﬁcant improvement in all domains
assessed.Conclusions: Transcatheter mitral valve repair with the MitraClip in prohibitive
surgical risk patients with DMR results in substantial improvement in QOL. Further
studies are needed to examine whether these results are durable and associated with
other improved clinical outcomes.Valvular disease - Mitral: Transcatheter therapies
(non-MitraClip)
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Background: Transapical off-pump mitral valve repair with Neochord implantation
(TOP-MINI) is a recently introduced minimally invasive technique to treat degener-
ative mitral valve prolapse or ﬂail. We sought to assess the safety, feasibility and
efﬁcacy of the TOP-MINI procedure.
Methods: From November 2013 to April 2014, 25 patients with severe symptomatic
degenerative mitral regurgitation (MR) with leaﬂet prolapse or ﬂail were treated.
Acute procedure success was deﬁned as postoperative residual MR less than moderate
(MR< 2+). At 1 and 3 months follow-up, we evaluated clinical conditions and
residual MR grade with transthoracic echocardiography.
Results: Median age was 76 years (range 31-90 years), median Euroscore-I was
5.98% (range 0.88-38.9%) and median STS score was 1.73% (range 0.22-14.6%).
Twenty one patients (84%) presented a posterior mitral leaﬂet prolapse, 3 (12%) an
anterior leaﬂet prolapse and 1 (4%) a combined anterior-posterior prolapse. The
procedure was successfully completed in all patients with correct chordae implantation
achieving a signiﬁcant MR reduction. A median of 4 Gore-Tex Neochords (range 3-6)
were implanted for each patient: 8 patients (32%) received 3 chordae, 12 (48%)
received 4 chordae, 4 (16%) had 5 chordae and 1 (4%) had 6 chordae. Median pro-
cedural time was 135 min (range 90-200 min). No death, stroke, acute myocardial
infarction or bleeding events occurred within 30-days. At 1 month and 3 months
follow-up 22 patients (88%) were in good clinical conditions (NYHA I or II) with
residual MR < 2+. Ten patients (40%) presented no MR, 6 (24%) mild MR (1+) andCT Abstracts/Valvular disease - Mitral: Transcatheter therapies (non-MitraClip)
